ARVO '26: TKIs for Wet AMD and How We Got to the AI Era of Research

TKIs are all the rage. But what do the data tell us about their ability to effectively treat wet AMD? Akshay Thomas, MD, outlines findings from DAVIO 2, the phase 2 study assessing the safety and efficacy of EYP-1901 (EyePoint Pharmaceuticals) for the treatment of wet AMD.

And Aaron Lee, MD, MSCI, and Cecelia Lee, MD, MS, recap their Cogan Award Lecture from this year’s ARVO annual meeting. Hear how they envision a future of ophthalmic research driven by AI and machine learning—and how they know we can only get there by looking back at where we've been.